Combined blockade of programmed death-1 (PD-1) and TGF-β1 effectively restores the functionality of CD8+ T cells, underscoring the potential therapeutic value of targeting these pathways in order to reinvigorate anti-tumor immune responses (102). The gene discussed is CD8A; the disease is neoplasm.